AEBR reduces matrix metalloproteinase 2 (MMP2), matrix metalloproteinase 9 (MMP9), and urokinase plasminogen activator (uPA) expression in mouse tumor tissues and also restrains VEGF activity and thus angiogenesis in the tumor tissue.32-34. Here, MMP9 is linked to neoplasm.